The use of rabbit polyclonal antibodies to assess neoantigenicity following viral reduction of an alpha-1-proteinase inhibitor preparation

Biologicals

Volumn 34, Issue 3, 2006, Pages 199-207

  Doyle, James W ^a   Johnson, Gary L ^b   Eshhar, Nomi ^c   Hammond, David ^d  

^a Plasma Derivatives Laboratory   (United States)

^b Immunochemistry Technologies   (United States)

^c Kamada Ltd   (Israel)

^d AMERICAN RED CROSS   (United States)

Author keywords

Alpha 1 antitrypsin; Alpha 1 proteinase inhibitor; Biological products; Blood proteins; Drug evaluation; Immunoenzyme techniques; Immunoglobulins; Neoantigens; Preclinical

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIGEN; ANTISERUM; DETERGENT; EPITOPE; POLYCLONAL ANTIBODY; SOLVENT; TRINITROPHENYL;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MANUFACTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; INOCULATION; NANOFILTRATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; VALIDATION PROCESS;

ALPHA 1-ANTITRYPSIN; ANIMALS; ANTIBODIES; ANTIGENS, VIRAL; DRUG CONTAMINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; RABBITS; ULTRAFILTRATION;

ORYCTOLAGUS CUNICULUS;

EID: 33747224280     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2005.09.006     Document Type: Article

References (30)

1. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 18 (2003) 1257-1259
2. Peerlinck K., Arnout J., Gilles J.G., Saint-Remy J.-M., and Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 69 (1993) 115-118
3. Rosendaal F.R., Nieuwenhuis H.K., van den Berg H.M., Heijboer H., Mauser-Bunschoten E.P., van den Meer J., et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 81 (1993) 2180-2186
4. Laub R., Di Giambattista M., Fondu P., Brackmann H.-H., Lenk H., Saenko E.L., et al. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Thromb Haemost 81 (1999) 39-44
5. Bussiere J.L. Animal models as indicators of immunogenicity of therapeutic proteins in humans. In: Brown F., and Mire-Sluis A.R. (Eds). Immunogenicity of therapeutic biological products 112 (2003), Karger AG, Basel 135-139
6. Bugelski P.J., and Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 6 (2004) 10-16
7. Chen S.X., Hammond D.J., Lang J.M., and Lebing W.R. Purification of α1-proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography. Vox Sang 74 (1998) 232-241
8. Bluestein H., and Pierce C.W. Development of primary γM, γG, and γA anti-TNP plaque-forming cell responses in vitro. J Immunol 111 (1973) 130-136
9. Habeeb A.F.S.A. Determination of free amino groups in protein by trinitrobenzene sulfonic acid. Anal Biochem 14 (1966) 328
10. Crowther J.R. ELISA. Theory and practice. Methods Mol Biol 42 (1995) 38-39 131-60
11. Findlay J.W.A., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 21 (2000) 1249-1273
12. Press W.H., Teukolski S.A., Vetterling W.T., and Flannery B.P. Numerical recipes in C: the art of scientific computing. 2nd ed. (2002), Cambridge University Press, New York p. 683-8
13. Dean R.B., and Dixon W.J. Simplified statistics for small numbers of observations. J Anal Chem 23 (1951) 636-638
14. Dichtelmüller H., Rudnick D., and Kloft M. Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulins. Biologicals 30 (2002) 135-142
15. Korneyeva M., Hotta J., Lebing W., Rosenthal R.S., Franks L., and Petteway Jr. S.R. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 30 (2002) 153-162
16. Johnston A., Uren E., Johnstone D., and Wu J. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies. Biologicals 31 (2003) 213-221
17. Blümel J., Schmidt I., Effenberger W., Seitz H., Willkommen H., Brackmann H.H., et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 42 (2002) 1473-1481
18. Burnouf T., and Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 9 (2003) 24-37
19. Yunoki M., Urayama T., Tsujikawa M., Sasaki Y., Abe S., Takechi K., et al. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations. Br J Haematol 128 (2005) 401-404
20. Suontaka A.M., Blombäck M., and Chapman J. Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion 43 (2003) 568-575
21. Wang J., Mauser A., Chao S.F., Remington K., Treckmann R., Kaiser K., et al. Virus inactivation and protein recovery in a novel ultraviolet-C reactor. Vox Sang 86 (2004) 230-238
22. Drohan W.N., Miekka S.I., Griko Y.V., Forng R.Y., Stafford R.E., Hill C.R., et al. Gamma irradiation of intravenous immunoglobulin. Dev Biol (Basel) 118 (2004) 133-138
23. Edwards C.A., Piet M.P., Chin S., and Horowitz B. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 52 (1987) 53-59
24. Horowitz B., Bonomo R., Prince A.M., Chin S.N., Brotman B., and Shulman R.W. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 79 (1992) 826-831
25. Braun A., Kwee L., Labow M.A., and Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal transgenic mice. Pharm Res 10 (1997) 1472-1478
26. Vitex provides an update on the development program for INACTINE™ pathogen inactivation system for red blood cells [online news report]. PRNewswire-FirstCall. Nov 23, 2004. Available from: URL: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/sto ry/11-23-2004/0002499244&EDATE=.
27. Ronneberger H. Assay of possible formation of antigenic components in heat-treated plasma protein preparations. Arch Toxicol Suppl 9 (1986) 447-450
28. MacGregor I.R., McLaughlin L.F., MacGregor M.C., Prowse C.V., and Pepper D.S. No detectable alterations in immunogenicity following terminal severe dry-heat treatment of high-purity factor VIII (liberate) and factor IX (HP9) concentrates. Vox Sang 69 (1995) 319-327
29. Cierniewski C.S., Pluskota E., Cieslak M., Brodniewicz T., and Nowotarski M. Antigenic properties of fibrinogen component of Hemaseel™ HMN subjected to the antiviral severe dry heat treatment. Thromb Res 82 (1996) 349-359
30. Reipert B.M., Schoppmann A., and Schwarz H.P. A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions. Thromb Haemost 89 (2003) 1110-1112